Overview Financials News + Filings Key Docs Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
WESTMOUNTAIN Co (WASM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/24/2018 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"CONSENT",
"2. Summary of Critical Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America . Principles of Consolidation The consolidated financial statements include the accounts of CytoBioscience, Inc., and its wholly owned subsidiaries, Cytocentrics Bioscience GmbH, Cytocentrics B.V. and SolubleBioscience, Inc. . All intercompany balances have been eliminated in consolidation. Foreign Currency Translation For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the year and the exchange rate at the balance sheet date, to translate the operating results and financial position to U.S. dollar, the...",
"WestMountain Company and CytoBioscience, Inc. Pro-Forma Condensed Consolidated Balance Sheet For the year ended December 31, 2017 WestMountain CytoBioscience Adjustments Pro Forma Combined" |
|
|
|